Skip Ribbon Commands
Skip to main content
Professor Chow Kah Hoe Pierce from National Cancer Centre Singapore

Prof Chow Pierce Kah Hoe

MBBS (NUS), M.Med (Surg), FRCS (Edinburgh), FAMS (Gen Surg), PhD

Senior Consultant

Specialty: Surgical Oncology

Clinical Appointments

  • Senior Consultant Division of Surgical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Senior Consultant Hepato-pancreato-biliary and Transplant Surgery Singapore General HospitalSingapore General Hospital

Academic Appointments

  • Professor and Course Director

Profile

Prof Pierce Chow is senior consultant and Co-Director (Surgical) of the Comprehensive Liver Cancer Clinic at the National Cancer Centre Singapore, Senior Consultant Surgeon in HPB and Transplant Surgery at the Singapore General Hospital and Professor and Course Director at Duke-NUS Medical School Singapore.

Prof Chow was the Chapter of Surgeon’s Gold Medallist at the conjoint Royal College of Surgeons of Edinburgh/M.Med (Surgery) examination in 1994 and subsequently completed a clinical fellowship in Liver Transplantation in Australia in 2000. In 2002 he was awarded his PhD. 

In addition to managing a busy HPB surgical oncology service, Prof Chow has researched extensively on hepatocellular carcinoma (HCC). He leads collaborative research on the genomic heterogeneity of HCC and applications in precision medicine. He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group in 1997 and has been the protocol chair of 5 multi-national trials. In 2012 the National Medical Research Council Singapore conferred him the National Outstanding Clinician-Scientist Award for improving clinical outcomes of patients with his research on Liver Cancer. 

Prof Chow was awarded the NMRC Translational-Clinical Research Grant for the Flagship Program in Liver Cancer in 2016 and has commenced the multi-national PLANET study (Precision Medicine in Liver Cancer Asia-Pacific Network). 

Education

  • PhD, National University of Singapore 
  • FAMS (General Surgery), Academy of Medicine, Singapore 
  • USMLE, United States Medical Licensing Examination 1 and 2 
  • Certificate of Specialist Accreditation, Singapore Medical Council 
  • FRCS (Edinburgh) 
  • M.Med. (Surgery), National University of Singapore 
  • MBBS, National University of Singapore 

Professional Appointments and Committee Memberships

  • President, College of Clinician Scientists Singapore 
  • Council, Asia-Pacific Primary Liver Cancer Expert Association 
  • Council, Academy of Medicine Singapore  
  • Protocol Chair, Asia-Pacific Hepatocellular Carcinoma Trials Group 
  • Member, Research Training Review Panel, Specialists Accreditation Board, Ministry of Health 
  • Member, Research Committee, Specialists Accreditation Board, Ministry of Health
  • Member, Complaints Panel, Singapore Medical Council 
  • Member, American Society of Clinical Oncology 
  • Member, International Hepato-Pancreato-Biliary Association Scientific Committee 
  • Member, Asia-Pacific Hepato-Pancreato-Biliary Association

Awards

  • National Day Awards, Long Service Medal 2016 
  • National Outstanding Clinician Scientist Award, NMRC, 2012 
  • Outstanding Educator Award, Duke-NUS Graduate Medical School 2010 
  • Excellent Service Award (Gold), Healthcare. Spring Singapore 2004 
  • Young Surgeon’s Award, Academy of Medicine, Singapore 1995
  • Chapter of Surgeon’s Gold Medal Conjoint M.Med /FRCS (Edinburgh) 1994

Publications and Research Trials

  • W. Zhai, T. K. Lim, T. Zhang, S. T. Phang, Z. Tiang, P. Guan, M. H. Ng, J. Q. Lim, F. Yao, Z. Li, P. Y. Ng, J. Yan, B. K. Goh, A. Y. Chung, S. P. Choo, C. C. Khor, W. W. Soon, K. W. Sung, R. S. Foo, and P. K. Chow, "The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma," Nat Commun, vol. 8, p. 4565, Feb 27 2017. 
  • A. Qamra, M. Xing, N. Padmanabhan, J. J. Kwok, S. Zhang, X. Chang, Y. S. Leong, A. P. Lee Lim, Q. Tang, W. Ooi, J. Suling Lin, T. Nandi, X. Yao, X. Ong, M. Lee, S. T. Tay, A. T. Keng, E. Gondo Santoso, C. C. Ng, A. Ng, A. Jusakul, D. Smoot, H. Ashktorab, S. Y. Rha, K. G. Yeoh, W. Peng Yong, P. K. Chow, W. H. Chan, H. S. Ong, K. C. Soo, K. M. Kim, W. K. Wong, S. G. Rozen, B. T. Teh, D. Kappei, J. Lee, J. Connolly, and P. Tan, "Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma," Cancer Discov, Mar 20 2017. 
  • M. Garnelo, A. Tan, Z. Her, J. Yeong, C. J. Lim, J. Chen, K. H. Lim, A. Weber, P. Chow, A. Chung, L. L. Ooi, H. C. Toh, M. Heikenwalder, I. O. Ng, A. Nardin, Q. Chen, J. P. Abastado, and V. Chew, "Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma," Gut, vol. 66, pp. 342-351, Feb 2017. 
  • W. F. Ooi, M. Xing, C. Xu, X. Yao, M. K. Ramlee, M. C. Lim, F. Cao, K. Lim, D. Babu, L. F. Poon, J. Lin Suling, A. Qamra, A. Irwanto, J. Qu Zhengzhong, T. Nandi, A. P. Lee-Lim, Y. S. Chan, S. T. Tay, M. H. Lee, J. O. Davies, W. K. Wong, K. C. Soo, W. H. Chan, H. S. Ong, P. Chow, C. Y. Wong, S. Y. Rha, J. Liu, A. M. Hillmer, J. R. Hughes, S. Rozen, B. T. Teh, M. J. Fullwood, S. Li, and P. Tan, "Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity," Nat Commun, vol. 7, p. 12983, Sep 28 2016. 
  • M. Gandhi, S. P. Choo, C. H. Thng, S. B. Tan, A. S. Low, P. C. Cheow, A. S. Goh, K. H. Tay, R. H. Lo, B. K. Goh, J. S. Wong, D. C. Ng, K. C. Soo, W. M. Liew, and P. K. Chow, "Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial," BMC Cancer, vol. 16, p. 856, Nov 07 2016. 
  • P. K. Chow, S. P. Choo, D. C. Ng, R. H. Lo, M. L. Wang, H. C. Toh, D. W. Tai, B. K. Goh, J. S. Wong, K. H. Tay, A. S. Goh, S. X. Yan, K. S. Loke, S. P. Thang, A. Gogna, C. W. Too, F. G. Irani, S. Leong, K. H. Lim, and C. H. Thng, "National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma," Liver Cancer, vol. 5, pp. 97-106, Apr 2016. 
  • J. C. J. Allen, J.-C. Nault, G. Zhu, A. Y. K. Khor, J. Liu, T. K. H. Lim, J. Zucman-Rossi, and P. K. H. Chow, "The transcriptomic G1–G6 signature of hepatocellular carcinoma in an Asian population: Association of G3 with microvascular invasion," Medicine, vol. 95, p. e5263, 2016.
  • F. Li, H. Huynh, X. Li, D. A. Ruddy, Y. Wang, R. Ong, P. Chow, S. Qiu, A. Tam, D. P. Rakiec, R. Schlegel, J. E. Monahan, and A. Huang, "FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors," Cancer Discovery, February 11, 2015 2015.
  • K. K. Huang, J. R. McPherson, S. T. Tay, K. Das, I. B. Tan, C. C. Ng, N. Y. Chia, S. L. Zhang, S. S. Myint, L. Hu, V. Rajasegaran, D. Huang, J. L. Loh, A. Gan, A. N. Sairi, X. X. Sam, L. T. Dominguez, M. Lee, K. C. Soo, L. L. Ooi, H. S. Ong, A. Chung, P. K. Chow, W. K. Wong, S. Selvarajan, C. K. Ong, K. H. Lim, T. Nandi, S. Rozen, B. T. Teh, R. Quek, and P. Tan, "SETD2 histone modifier loss in aggressive GI stromal tumours," Gut, Sep 3 2015 
  • W. Wang, N. G. Iyer, H. T. Tay, Y. Wu, T. K. Lim, L. Zheng, I. C. Song, C. K. Kwoh, H. Huynh, P. O. Tan, and P. K. Chow, "Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma," BMC Cancer, vol. 15, p. 828, 2015.

Research Trials

  • Precision Medicine in Liver Cancer across an Asia-Pacific Network 
  • Post-SIR Spheres® surgery study (P4S): a retrospective analysis in patients with primary liver tumours or secondary hepatic metastases 
  • Phase III Multi‐Centre Open‐Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib In Locally Advanced Hepatocellular Carcinoma (SIRveNIB) 
  • Development of a Hepatocellular Carcinoma Outcomes Decision Model to Perform Cost Utility Analysis of Resection Versus Transplantation in Child-Pugh Class A Patients Fulfilling The Milan Criteria 
  • A Phase III randomized, double-blind, placebo-controlled study of Sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation 
  • Randomized double blind trial of Megastrol Acetate versus Placebo for the treatment of inoperable hepatocellular carcinoma
  • Phase I/II study of SIR-Spheres plus Sorafenib (Chemo-radiotherapy) as first line treatment in patients with non-resectable primary hepatocellular carcinoma